期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

西格列汀治疗新诊断2型糖尿病患者临床观察 被引量：4

Clinical observation of sitagliptin in the treatment of newly diagnosed type 2 diabetes
下载PDF
导出
摘要 目的评价西格列汀治疗新诊断2型糖尿病的疗效。方法将84例新诊断2型糖尿病患者随机分为2组,治疗组42例,治疗组用西格列汀进行治疗,对照组42例应用二甲双胍治疗,观察12周。比较2组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1C)、体质量指数(BMI)的变化。结果治疗12周后,治疗组与对照组的FBG,2hPG,HbA1C和BMI均下降(P<0.05),西格列汀组较对照组治疗后各项指标组间差异不明显(P>0.05),但西格列汀组满意度更高。结论西格列汀控制新诊断2型糖尿病疗效确切,具有很好的降糖效果和依从性。 Objective To evaluate the efficacy and safety of sitagliptin in newly diagnosed type 2 diabetes patients. Method 84 newly diagnosed T2DM patients were divided randomly in to two groups, receiving sitagliptin group and metformin control group for 12 weeks. Result After treated 12 weeks,FPG,2 h PG, HbA1C and BMI in 2 groups were decreased than before （P〈0.05） ; there were no statistical difference between the sitagliptin and the control group（P〈0.05）. Conclusion Sitagliptin could control the glycemia effectively in newly diagnosed T2DM patients, and could achieve better benefit in reducing BMI and patient-based compliance.
作者 周岩 宋菲菲 吴大方 曹晋
机构地区 解放军
出处 《西北药学杂志》 CAS 2013年第4期414-416,共3页 Northwest Pharmaceutical Journal
关键词 西格列汀 新诊断 2型糖尿病 sitagliptin newly diagnosed type 2 diabetes
分类号 R977 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1马艳红,刘涛,刘景晶,李泰明.胰高血糖素样肽-1及其类似物的研究进展[J].西北药学杂志,2011,26(6):482-484. 被引量：4
  • 2Duttaroy A, Voelker F,Merriam K,et al. The DPP-4 in-hibitor vildagliptin increases pancreatic beta cell neogen-esis and decreases apoptosis [J]. Diabetes, 2005,54(1):A141.
  • 3Mohan V, Yang W, Son H Y, et al. Efficacy and safetyof sitagliptin in the treatment of patients with type 2 di-abetes in China, India, and Korea [J]. Diabet Res ClinPract,2009,83(1) : 106-116.
  • 4Aschner P’Katzef H L,Guo H,et al. Eficacy and safetyof monotherapy of sitagliptin compared with metforminin patients with type 2 diabetes[J]. Diabet Obes Metab,2010,12(1):1-10.
  • 5Lwamoto Y, Tajima N. Kadowaki T, et al. Eficacy andsafety of sitagliptin monotherapy compared with voglib-ose in Japanese patients with type 2 diabetes : a random-ized, double: blind trial[J], Diabet Obes Metab,2010,12(7):613-622.
  • 6Nonaka K,Kakikawa T, Sato A,et al. Eficacy and safetyof sitagliptin monotherapy in Japanese patients with type2 diabetes [J]. Diabet Res Clin Pract,2008,79 (2) : 291-298.
  • 7Herman D W,Round E,Swern A S,et al. Safety and tol-era-bility of sitagliptin in patients with type 2 diabetes:apooled analysis[J]. BMC Endocr Disord,2008,8(1) : 14.
  • 8Herman D W,Johnson J,Teng R,et al. Eficacy and safe-ty of initial combination therapy with sitagliptin andmetformin in patients with type 2 diabetes: a 54-weekstudy[J], Curr Med Res 0pin,2009,25(3) :569-583.
  • 9Herman D W,Johnson J,Teng R,et al. Eficacy and safe-ty of sitagliptin and metformin as imtial combinationtherapy and as monotherapy over 2 years in patientswith type 2 diabetes [J]. Diabet Obes Metab, 2010. 12(5):442-451.
  • 10Vils T,Rosenstock J, Yki-Jarvinen H, et al. Eficacy andsafety of sitagliptin when added to insulin therapy in pa-tients with type 2 diabetes [ J]. Diabet Obes Metab,2010,12(2):167-177.

二级参考文献28

  • 1Bell GI, Sanchez-pescador R, Laybourn PJ, et al. Exon duplication and divergene in the human preproglueagoon gene [J]. Nature, 1983,304(5924) :368-371.
  • 2Lopez LC, Frazier ML, Su CJ, et al. Mammalian pancreatic preproglucagon contains three glucagon-related peptides[J]. Proc Natl Acad Sci USA,1983,80 (18),5485-5489.
  • 3Parker JC, Andrews KM, Rescek DM, et al. Structure- function analysis of a series of glucagon-like peptide-1 analogs [J].J Pept Res, 1998,52 : 398-409.
  • 4Chang XQ,Keller D,O'Donoghue SI, et al. NMR studies of the aggregation of glucagon-like peptide-1., formation of a symmetric helical dimmer [J].FEBS Lett, 2002, 515:165-170.
  • 5Adelhorst K, H edegaard BB, Knudsen LB, et al. Structure activity studies of glucagon-like peptide-1 [J]. J Biol Chem, 1994,269 : 6275-6278.
  • 6Siegel EG,Gallwitz B, Scharf G, et al. Biological activity of GLP-l-analogues with N-terminal modifications[J].Regul Pept, 1999,79 : 93-102.
  • 7Geelhoed-Duijvestijn PH. Incretins: a new treatment option for type 2 diabetes[J]. Neth J Med,2007,65:60-64.
  • 8Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemi- a/reperfusion injury [J].Diabetes,2005,54 : 146-151.
  • 9Nystr MT,Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease [J].Am J Physiol Endocrinol Metab,2004,287 :E1209-1215.
  • 10Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventrieular dysfunction after successful reperfusion[J]. Circulation 2004,109 : 962-965.

同被引文献35

  • 1吕霄,赵猛,凌宏威,李伟.西格列汀对糖尿病前期人群的干预效果[J].中国老年学杂志,2014,34(1):26-29. 被引量：27
  • 2相爱霞,陈成华,董砚虎.糖尿病神经病变研究进展[J].国外医学（内分泌学分册）,2004,24(6):424-425. 被引量：9
  • 3左文标,王宁,张春香,钱春平.老年糖尿病周围神经病变的相关危险因素研究[J].实用老年医学,2007,21(1):24-26. 被引量：9
  • 4Hoghes R A.Peripheral neuropathy[J].BMJ,2002,324(7335):466-469.
  • 5Mayfield J A,Caps M T,Boyko E J,et al.Relationship of medial arterial calcinosis to autonomic neuropathy and adverse outcomes in a diabetic veteran population[J].J Diabetes Complicat,2002,16(2):165-171.
  • 6卫生部疾病控制司,中华医学会糖尿病分会,2010中国糖尿病防治指南[EB/OL].2010-12-05).http://wenku.baidu.com/view/eb245e0052acfc789ebgc9el.html.
  • 7Yang WY,Lu JM,Weng JP,et al.Prevalance of diabetes among men and women in China[J].N Engl J Med,2010,362(12):1090-1102.
  • 8Mastsuyama Yokono A,Tahara A5Nakano R,et al.Antidiabetic effects of dipeptidyl peptidase- Ⅳ inhibitors and sulfonylures in streprozorocin-nicotinam ide-induced midly diabetic mice[J].Metabolism,2009,58(3):379-386.
  • 9Wen YY.Prevaience of diabetes among men and women in China[J].N Eng J Med,2010,362:11-13.
  • 10Ahern B.DPP-4 inhibitors[J].Best Pract Clin Ehdocrinol Metab,2007,21:517-533.

引证文献4

二级引证文献44

西北药学杂志
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部